Neurocrine Biosciences Inc (NBIX) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Neurocrine Biosciences Inc   (NASDAQ: NBIX)
 

Neurocrine Biosciences Inc Growth Comparisons

Select each growth Category to receive further Information





NBIX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 41.24 % 5.15 % 10.18 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 17.07 % -11.92 % -2.46 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 37.98 % 5.66 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 9.72 % 1.16 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 22.29 % 8.24 % 8.67 % 13.63 %


NBIX's Growth Comparisons in III. Quarter 2026




Facing 41.24% year on year sales decrease in the third quarter 2026, to $ 1.12 billions, Neurocrine Biosciences Inc reported smaller declines than the Biotechnology & Pharmaceuticals industry with 5.15%, and less than 10.18% improvement in the Healthcare sector. Despite the modest Sales rises in theHealthcare sector and the Biotechnology & Pharmaceuticals industry, Neurocrine Biosciences Inc reported above average market Sales growth.

Top-line improved by 17.07% from the second quarter. Looking into annual sales rise of 22.29%, and S & P 500's average yearly sales growth is 13.63% over the five years, including only Businesses with the third quarter 2026 Results. Neurocrine Biosciences Inc grew faster than the market.

NBIX Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Product
-
63.39 %
Collaboration Revenue
-
45.12 %
Reportable
-
63.3 %
Total
41.24 %
17.07 %


Growth Rates of NBIX's Income in the third quarter 2026


NBIX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) 38.62 % 440.4 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) 118.68 % -48.71 % -12.21 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) 61.23 % 996.83 % 30.98 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) 11.61 % 230.02 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change 30.59 % -18.52 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) -1.43 % -78.38 % -38.86 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) 43.01 % - -63.27 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) 64.14 % -86.28 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) -0.43 % -58.33 % -4.67 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 3.28 % -11.53 % 8.91 % -28.64 %

NBIX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) -1.43 % -79.71 % -39.2 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) 43.01 % -87.33 % 11.78 % 27.07 %
Y / Y Net Income Change (Q3 TTM) 64.14 % 102.94 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) -0.43 % -7.86 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth 3.28 % -8.71 % 9.08 % 23.95 %

NBIX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) -3.79 % -81.2 % -38.86 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) 41.96 % - -63.27 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) 61.61 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) -1.13 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 1.89 % 38.54 % 8.91 % -28.64 %



NBIX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) -3.92 % -82.35 % -39.2 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) 41.01 % -88.49 % 11.78 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) -1.17 % - 10.63 % 4.93 %
EPS Net 5 Year Avg. Change 2.34 % -8.71 % 9.08 % 23.95 %



Facing -3.92% year on year income per share decrease in the third quarter, to $ 1.96, Neurocrine Biosciences Inc reported smaller declines than the Biotechnology & Pharmaceuticals industry with -82.35%, and less than -39.2% slide in the Healthcare sector. Slow third quarter 2026 income per share in Biotechnology & Pharmaceuticals industry and Healthcare sector, were portrayed in Neurocrine Biosciences Inc 's results, which underperformed overall market.

The bottom-line grew by 41.01% from the second quarter. Average yearly income per share growth for Neurocrine Biosciences Inc is 2.34%, while S & P 500's average annual income per share increase is 23.95% over the five years, including only Businesses with the third quarter 2026 earnings reports.

NBIX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) 79 % 6160.46 % 44.26 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) 198.29 % -53.34 % -42.65 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) 74.89 % 10.87 % 19.33 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) 19.5 % 17.82 % 5.88 % 15.75 %
Free Cash Flow 5 Year Avg. Change 28.04 % -13.86 % 0.42 % 1.8 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - 33.74 % - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - 783.99 % - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change 45.03 % 23.25 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -12.12 % 31.06 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) 48.72 % -4.21 % -19.32 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) -29.29 % 9.75 % 9.34 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) -4.92 % 6.42 % 0.99 % 23.05 %
Capital Expenditures 5 Year Avg. Change 25.55 % 9.64 % 8.61 % 14.19 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.